ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical business dedicated to finding and developing small molecule medicines that target cancer's underlying biological pathways. It employs an integrated discovery engine to find targets and produce small molecule new chemical entities, or NCEs, with features that it believes could result in potentially distinct product profiles. Its pipeline includes two lead product candidates: ZN-c5, which is being developed for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer, and ZN-c3, which is being developed for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
ZENTALIS PHARMACEUTICALS
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2014-12-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.zentalis.com
Total Employee:
101+
Status:
Active
Contact:
212-433-3791
Email Addresses:
[email protected]
Total Funding:
896.6 M USD
Technology used in webpage:
Amazon CrUX Top 50m Amazon S3 Cox Communications
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Pfizer
Pfizer investment in Post-IPO Equity - Zentalis Pharmaceuticals
Redmile Group
Redmile Group investment in Series C - Zentalis Pharmaceuticals
Viking Global Investors
Viking Global Investors investment in Series C - Zentalis Pharmaceuticals
Eventide
Eventide investment in Series C - Zentalis Pharmaceuticals
Matrix Capital
Matrix Capital investment in Series C - Zentalis Pharmaceuticals
Perceptive Advisors
Perceptive Advisors investment in Series C - Zentalis Pharmaceuticals
Surveyor Capital
Surveyor Capital investment in Series C - Zentalis Pharmaceuticals
Matrix Capital
Matrix Capital investment in Series B - Zentalis Pharmaceuticals
Viking Global Investors
Viking Global Investors investment in Series B - Zentalis Pharmaceuticals
Key Employee Changes
Official Site Inspections
http://www.zentalis.com Semrush global rank: 2.44 M Semrush visits lastest month: 7.71 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Zentalis Pharmaceuticals"
Zentalis Pharmaceuticals
About Zentalis. Improving Patient lives. We are a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. …See details»
IR Home - zentalis.com
Zentalis Pharmaceuticals is a New York City and San Diego based biotech company dedicated to the discovery and development of clinically differentiated small molecules targeting …See details»
Zentalis Pharmaceuticals - Crunchbase Company …
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical business dedicated to finding and developing small molecule medicines that target cancer's underlying biological pathways. It employs an integrated discovery engine to …See details»
Investors/Media Home | Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a San Diego based biotech company dedicated to the discovery and development of clinically differentiated small molecules targeting fundamental biological pathways of cancer. Recent News. Learn More. Events …See details»
Zentalis Pharmaceuticals - LinkedIn
Zentalis is proud to join other companies, organizations, and individuals in helping support this important program. Dr. Zhu is currently a hematology and oncology fellow at Baylor College of ...See details»
Zentalis Pharmaceuticals Appoints Oncology Clinical Development …
“I am excited to lead Zentalis, an organization that has an extremely talented team, immense support from its investors, and an impressive pipeline of oncology candidates. The Zentalis …See details»
CORPORATE PRESENTATION March 2022 - Zentalis Pharmaceuticals
Zentalis intends to evaluate ZN-c3 in combination with niraparib (ZEJULA®), as part of a clinical research collaboration with GlaxoSmithKline. Zentalis maintains full ownership of ZN-c5 and …See details»
Zentalis Pharmaceuticals Announces Executive Leadership …
Nov 13, 2024 Scott Myers appointed to the Board of Directors as Chairperson SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a …See details»
Zentalis Pharmaceuticals Announces Executive Leadership …
Nov 13, 2024 About Zentalis Pharmaceuticals Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule …See details»
Zentalis Pharmaceuticals Strengthens Management Team with Key …
Jan 25, 2024 Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer Kyle Rasbach, Ph.D., Pharm.D., Experienced Biotechnology Portfolio ...See details»
Contact - Zentalis Pharmaceuticals
Reach out to Zentalis for inquiries, collaborations, or to learn more about our groundbreaking cancer therapies and research efforts. Contact our dedicated team today. About Us. Our …See details»
Zentalis Pharma Reshapes Leadership, Advances Cancer Drug …
Nov 13, 2024 Zentalis appoints new CEO Julie Eastland and CMO as it prepares for pivotal trials of azenosertib, its promising cancer drug tested in 800+ patients. Learn about strategic …See details»
Zentalis Pharmaceuticals - Contacts, Employees, Board Members, …
Organization. Zentalis Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News ... 139. About. Zentalis Pharmaceuticals has 5 current employee …See details»
CORPORATE PRESENTATION SEPTEMBER 2021 - Zentalis …
Zentalis intends to evaluate ZN-c3 in combination with niraparib (ZEJULA®), as part of a clinical research collaboration with GlaxoSmithKline. Zentalis maintains full ownership of ZN-c5 and …See details»
Zentalis - Overview, News & Similar companies | ZoomInfo.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. …See details»
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical ...
Jun 18, 2024 Zentalis will host a live conference call and webcast today at 8:00 a.m. Eastern Time to provide a business update. To access the live conference call by telephone, please …See details»
Pipeline - Zentalis Pharmaceuticals
Explore Zentalis' robust pipeline of next-generation cancer therapies targeting difficult-to-treat cancers. Azenosertib is a potentially first-in-class and best-in-class oral WEE1 inhibitor in …See details»
Zentalis Pharmaceuticals Announces Fast Track Designation
Nov 17, 2021 Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental …See details»
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given ... - MarketBeat
1 day ago XTX Topco Ltd raised its position in shares of Zentalis Pharmaceuticals by 8.7% in the third quarter. XTX Topco Ltd now owns 194,062 shares of the company's stock worth …See details»
Integrated Discovery Engine - Zentalis Pharmaceuticals
Utilizing our integrated discovery engine to efficiently identify and develop novel oncology therapies. Leveraging our deep industry experience and knowledge, we have built our …See details»